Shares of Poseida Therapeutics, Inc. (NASDAQ:PSTX - Get Free Report) hit a new 52-week high during trading on Tuesday . The stock traded as high as $9.66 and last traded at $9.66, with a volume of 464888 shares. The stock had previously closed at $9.56.
Analyst Ratings Changes
A number of research firms have weighed in on PSTX. Cantor Fitzgerald downgraded Poseida Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Tuesday, November 26th. William Blair reiterated a "market perform" rating on shares of Poseida Therapeutics in a research report on Tuesday, November 26th. HC Wainwright reiterated a "neutral" rating and set a $9.00 price objective (down from $20.00) on shares of Poseida Therapeutics in a research note on Tuesday, November 26th. Piper Sandler downgraded shares of Poseida Therapeutics from an "overweight" rating to a "neutral" rating and set a $10.00 target price on the stock. in a research note on Monday, December 2nd. Finally, BTIG Research reiterated a "neutral" rating on shares of Poseida Therapeutics in a research report on Tuesday, November 26th. Five investment analysts have rated the stock with a hold rating, Based on data from MarketBeat, the stock has an average rating of "Hold" and an average target price of $9.50.
Read Our Latest Report on PSTX
Poseida Therapeutics Trading Down 0.6 %
The company has a market capitalization of $928.85 million, a P/E ratio of -15.08 and a beta of 1.63. The business has a 50 day moving average price of $6.94 and a 200 day moving average price of $4.35. The company has a current ratio of 3.20, a quick ratio of 3.20 and a debt-to-equity ratio of 0.68.
Insider Buying and Selling at Poseida Therapeutics
In other Poseida Therapeutics news, Chairman Mark J. Gergen sold 30,000 shares of the stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $9.27, for a total value of $278,100.00. Following the completion of the sale, the chairman now directly owns 651,291 shares in the company, valued at $6,037,467.57. This represents a 4.40 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 2.90% of the company's stock.
Hedge Funds Weigh In On Poseida Therapeutics
Several institutional investors and hedge funds have recently modified their holdings of the business. Fred Alger Management LLC bought a new position in Poseida Therapeutics in the third quarter valued at approximately $369,000. Barclays PLC lifted its position in Poseida Therapeutics by 132.7% in the 3rd quarter. Barclays PLC now owns 120,464 shares of the company's stock valued at $345,000 after acquiring an additional 68,688 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its stake in Poseida Therapeutics by 62.8% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 359,197 shares of the company's stock worth $1,027,000 after purchasing an additional 138,510 shares during the period. Renaissance Technologies LLC boosted its stake in Poseida Therapeutics by 53.4% in the 2nd quarter. Renaissance Technologies LLC now owns 854,900 shares of the company's stock worth $2,496,000 after purchasing an additional 297,500 shares during the period. Finally, Advantage Alpha Capital Partners LP bought a new position in Poseida Therapeutics during the 3rd quarter worth about $285,000. 46.87% of the stock is currently owned by institutional investors and hedge funds.
About Poseida Therapeutics
(
Get Free Report)
Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.
Featured Articles
Before you consider Poseida Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Poseida Therapeutics wasn't on the list.
While Poseida Therapeutics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
